Sol Gel Technologies Ltd (SLGL) - Total Assets
Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) holds total assets worth $53.76 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sol Gel Technologies Ltd - Total Assets Trend (2014–2025)
This chart illustrates how Sol Gel Technologies Ltd's total assets have evolved over time, based on quarterly financial data. Also see Sol Gel Technologies Ltd market cap and net worth for the company's overall valuation and market capitalisation.
Sol Gel Technologies Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Sol Gel Technologies Ltd's total assets of $53.76 Million consist of 90.2% current assets and 9.9% non-current assets. Review SLGL total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 36.9% |
| Accounts Receivable | $1.97 Million | 6.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Sol Gel Technologies Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SLGL share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sol Gel Technologies Ltd's current assets represent 90.2% of total assets in 2025, an increase from 35.2% in 2014.
- Cash Position: Cash and equivalents constituted 36.9% of total assets in 2025, up from 24.9% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is accounts receivable at 6.6% of total assets.
Sol Gel Technologies Ltd Competitors by Total Assets
Key competitors of Sol Gel Technologies Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Sol Gel Technologies Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.37 | 7.32 | 5.05 |
| Quick Ratio | 10.37 | 7.32 | 5.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $46.15 Million | $31.31 Million | $38.62 Million |
Sol Gel Technologies Ltd - Advanced Valuation Insights
This section examines the relationship between Sol Gel Technologies Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.71 |
| Latest Market Cap to Assets Ratio | 7.13 |
| Asset Growth Rate (YoY) | -16.5% |
| Total Assets | $29.92 Million |
| Market Capitalization | $213.40 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Sol Gel Technologies Ltd's assets at a significant premium (7.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Sol Gel Technologies Ltd's assets decreased by 16.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sol Gel Technologies Ltd (2014–2025)
The table below shows the annual total assets of Sol Gel Technologies Ltd from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $29.92 Million | -16.54% |
| 2024-12-31 | $35.85 Million | -20.85% |
| 2023-12-31 | $45.29 Million | -2.88% |
| 2022-12-31 | $46.63 Million | -32.61% |
| 2021-12-31 | $69.19 Million | +16.95% |
| 2020-12-31 | $59.16 Million | -3.49% |
| 2019-12-31 | $61.30 Million | -12.03% |
| 2018-12-31 | $69.68 Million | +354.99% |
| 2017-12-31 | $15.31 Million | +39.42% |
| 2016-12-31 | $10.98 Million | +33.25% |
| 2015-12-31 | $8.24 Million | +245.52% |
| 2014-12-31 | $2.39 Million | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more